Medical Equipment, Pharmaceuticals & Personal Care Tenders & Contracts

In accordance with the National Immunisation Advisory Committee Immunisation Guidelines of Ireland a National Contract for the Supply of Live Attenuated Influenza Vaccines (LAIV) to the HSE is required to vaccinate relevant cohorts and provide protection against Influenza. This contract will provide sufficient stock of LAIV to vaccinate relevant cohorts for the next 12 months. There is only one sole supplier of Live Attenuated Influenza Vaccines (LAIV) in Ireland.

Supply and Delivery Of Diphtheria, Tetanus And Pertussis (Acellular, Component) Vaccine (Adsorbed, Reduced Antigen(s) Content)

In accordance with National Immunisation Advisory Committee (NIAC) advice, HSE Public Health: National Health Protection, with Access & Integration and the National Women and Infants Health Programme wish to put in place a contract for a monoclonal antibody, Nirsevimab (Beyfontus®) for a third pathfinder immunisation programme to protect all babies from RSV disease born from 1st March 2026 to 28th February 2027. RSV is a common virus that causes respiratory infections in young babies. Babies under three months old get sicker with RSV than older children. Each winter in Ireland one in two newborns babies will get RSV and many will need medical care from their GP or the emergency department of a children’s hospital. Four out of a hundred new born babies are hospitalised due to RSV with some babies needing special treatment in intensive care units. Nirsevimab is currently the best way to protect babies from RSV. This contract will supply 50,000 doses of this drug for passive immunisation over a seven month period during the RSV season.

Purchase of various microimmune products

The Health Service Executive (HSE) intends to enter Direct Negotiations for the supply and delivery to the HSE of a Varicella Vaccine in accordance with the National Immunisation Advisory Committee Guidelines of Ireland (NIAC). This is following the Health Service Executive (HSE) inviting DPS tenderers to express their interest in submitting a tender whereby only one supplier responded with their intention to submit a tender.

The supply of Smallpox Vaccine (Imvanex)

The supply of Smallpox Vaccine (Imvanex)

The HSE wishes to invite tender submissions for the supply and delivery of approximately 1,200,000 doses of 6 in 1 (Diphtheria, Tetanus, acellular Pertussis, Hepatitis B, Inactivated Polio Vaccine, Haemophilus Influenza Type B Conjugate) Vaccine fully compatible with the current primary immunisation schedule in Ireland, to be delivered over approximately 5 years contract duration (approximately 240,000 doses per annum). The drawdown may vary by 20 percent depending on the cohort requirement. The HSE reserves the right to extend the contract duration by up to two years where actual demand is less than forecasted demand.

This Contract will cover the administration of flu vaccines to employees at various sites with the requirement for additional digital vouchers. The Contract will be for a maximum period of 12 months with no extension periods and one Contractor will be appointed to the Contract. It is estimated that the flu clinics will commence between mid-September and early December. Details of how to apply are in RFQ pack

The HSE wishes to invite Tender Submissions for the supply of up to 1.2 million doses of Human Seasonal Trivalent Influenza Vaccines for the 2026/2027 season. The requirement for Human Seasonal Trivalent Influenza Vaccines can include Cell Based, Egg Based or Recombinant Vaccines. The HSE reserves the right to award a portion of the total tendered dose amount to cohort specific vaccines. The HSE will confirm its requirements after evaluation, at Contract stage. Tenderers should include provision for an additional 200,000 doses or 17 percent of the potential awarded quantity as a contingency stock.

The HSE wishes to invite Tender submissions for the supply of up to 650,000 doses of Enhanced (adjuvanted) Inactivated Influenza Vaccines for older people for the 2026/2027 season. The drawdown may vary by up to 20 percent depending on the cohort requirements.

Contract for the supply of immunisation products indicated for the prevention of, or protection against, SARS-CoV-2 in Under-18s (2026). The contract was awarded for Lot 1, Under-18 SARS-CoV-2 vaccine, via a further competition conducted under the SARS-CoV-2 vaccine DPS (FTS ref: 2024/S 000-026083). Value - The contract value is withheld from publication pursuant to regulation 50(6)(b) of the Public Contracts Regulations 2015 (as amended) so as not to prejudice the legitimate commercial interest of the supplier.

Contract for the supply of immunisation products indicated for the prevention of, or protection against, SARS-CoV-2 in Under-18s (2026).

The provision of a vaccine to protect against meningococcal B (MenB) disease, to be used in the national childhood immunisation programme, as well as a targeted programme to protect at risk adults against Gonorrhoea. Value - The contract value is withheld from publication pursuant to regulation 94(2)(b) of the Procurement Act 2023, so as not to prejudice the legitimate commercial interest of the supplier.

Contract for the supply of immunisation products indicated for the prevention of, or protection against, SARS-CoV-2 in Adults (2026). A single contract has been awarded for two Lots: Lot 1, Adult SARS-CoV-2 vaccines with a shelf-life of 10 weeks or greater at 2°C to 8°C & Lot 2, non-mRNA SARS-CoV-2 vaccines, via a further competition conducted under the SARS-CoV-2 vaccine DPS (FTS ref: 2024/S 000-026083). Value - The contract value is withheld from publication pursuant to regulation 50(6)(b) of the Public Contracts Regulations 2015 (as amended) so as not to prejudice the legitimate commercial interest of the supplier.

Contract for the supply of immunisation products indicated for the prevention of, or protection against, SARS-CoV-2 in Adults (2026).